HCV focus Presidio is a clinical-stage pharma focused on small-molecule antivirals for hepatitis C, targeting NS5A and NS5B. Sales opportunities exist in partnering for late-stage development, co-formulation capabilities, and potential rights licensing to expand global HCV therapy access.

Small team leverage With 11-50 employees and a lean operating model, there is room for strategic collaborations with larger biotech and CROs to accelerate preclinical and clinical programs, while offering contingency manufacturing and global distribution partnerships.

Pan-genotypic aim The emphasis on pan-genotypic potency and once-daily oral dosing creates a compelling value proposition for collaboration with larger antivirals portfolios seeking resistance management and simplified regimens for diverse patient populations.

Financial runway Funding of around $100M coupled with modest current revenue suggests opportunity for co-development or milestone-based partnerships with pharmaceutical players to de-risk early-stage programs and advance them toward commercialization.

Tech and ops fit Utilizing standard enterprise tech stacks (cloud, analytics, and collaboration tools) indicates compatibility for joint digital health initiatives, data-sharing arrangements, and streamlined sponsor-vendor relationships with potential partners.